U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C14H19Cl2NO2
Molecular Weight 304.212
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of CHLORAMBUCIL

SMILES

OC(=O)CCCC1=CC=C(C=C1)N(CCCl)CCCl

InChI

InChIKey=JCKYGMPEJWAADB-UHFFFAOYSA-N
InChI=1S/C14H19Cl2NO2/c15-8-10-17(11-9-16)13-6-4-12(5-7-13)2-1-3-14(18)19/h4-7H,1-3,8-11H2,(H,18,19)

HIDE SMILES / InChI

Molecular Formula C14H19Cl2NO2
Molecular Weight 304.212
Charge 0
Count
Stereochemistry ACHIRAL
Additional Stereochemistry No
Defined Stereocenters 0 / 0
E/Z Centers 0
Optical Activity NONE

Chlorambucil is a bifunctional 12 alkylating agent of the nitrogen mustard type that has been found active against selected human 13 neoplastic diseases. Chlorambucil alkylates and cross-links DNA during all phases of the cell cycle, inducing DNA damage via three different methods of covalent adduct generation with double-helical DNA. Bone marrow suppression (anemia, neutropenia, thrombocytopenia) is the most commonly occurring side effect of chlorambucil. There are no known drug/drug interactions with chlorambucil.

CNS Activity

Curator's Comment: Data in rats only. Chlorambucil is ionized at physiological pH and thus minimally enters brain, with a brain/plasma concentration of only 0.02.

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Primary
LEUKERAN

Approved Use

LEUKERAN (chlorambucil) is indicated in the treatment of chronic lymphatic (lymphocytic) leukemia, malignant lymphomas including lymphosarcoma, giant follicular lymphoma, and Hodgkin’s disease. It is not curative in any of these disorders but may produce clinically useful palliation.

Launch Date

1957
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1.46 μg/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
259 ng/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
1.99 μg × h/mL
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
380 ng × h/mL
10 mg single, oral
dose: 10 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
0.94 h
40 mg single, oral
dose: 40 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
CHLORAMBUCIL plasma
Homo sapiens
population: UNHEALTHY
age: ADULT
sex: FEMALE / MALE
food status: FASTED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
1%
CHLORAMBUCIL plasma
Homo sapiens
population: UNKNOWN
age: UNKNOWN
sex: UNKNOWN
food status: UNKNOWN
Doses

Doses

DosePopulationAdverse events​
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Disc. AE: Irritability, Myoclonic jerks...
AEs leading to
discontinuation/dose reduction:
Irritability
Myoclonic jerks
Exaggerated startle response
Vomiting
Bone marrow depression (mild)
Abnormal EEG
Sources:
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Disc. AE: Convulsive seizure, Comatose...
AEs leading to
discontinuation/dose reduction:
Convulsive seizure
Comatose
Vomiting
Sources: Page: p.239
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Co-administed with::
cimetidine, p.o(600 mg; single)
aspirin
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: M
Population Size: 1
Sources:
Disc. AE: Acute renal failure, Seizures...
AEs leading to
discontinuation/dose reduction:
Acute renal failure
Seizures
Sources:
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Disc. AE: Bone marrow depression, Carcinogenicity...
AEs leading to
discontinuation/dose reduction:
Bone marrow depression
Carcinogenicity
Infertility
Sources: Page: p.1
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Disc. AE: Convulsions, Metastases...
AEs leading to
discontinuation/dose reduction:
Convulsions
Metastases
Leukemia
Sources: Page: p.2
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Disc. AE: Skin rash, Erythema multiforme...
AEs leading to
discontinuation/dose reduction:
Skin rash (rare)
Erythema multiforme (rare)
Toxic epidermal necrolysis (rare)
Stevens-Johnson syndrome (rare)
Sources: Page: p.3
AEs

AEs

AESignificanceDosePopulation
Abnormal EEG Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Exaggerated startle response Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Irritability Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Myoclonic jerks Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Vomiting Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Bone marrow depression mild
Disc. AE
3.2 mg/kg single, oral
Overdose
Dose: 3.2 mg/kg
Route: oral
Route: single
Dose: 3.2 mg/kg
Sources:
healthy, 1.8
n = 1
Health Status: healthy
Age Group: 1.8
Sex: F
Population Size: 1
Sources:
Comatose Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Convulsive seizure Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Vomiting Disc. AE
5 mg/kg single, oral
Overdose
Dose: 5 mg/kg
Route: oral
Route: single
Dose: 5 mg/kg
Sources: Page: p.239
healthy, 2.5
n = 1
Health Status: healthy
Age Group: 2.5
Sex: M
Population Size: 1
Sources: Page: p.239
Acute renal failure Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Co-administed with::
cimetidine, p.o(600 mg; single)
aspirin
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: M
Population Size: 1
Sources:
Seizures Disc. AE
250 mg single, oral
Overdose
Dose: 250 mg
Route: oral
Route: single
Dose: 250 mg
Co-administed with::
cimetidine, p.o(600 mg; single)
aspirin
Sources:
healthy, 38
n = 1
Health Status: healthy
Age Group: 38
Sex: M
Population Size: 1
Sources:
Bone marrow depression Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Carcinogenicity Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Infertility Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.1
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.1
Convulsions Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Leukemia Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Metastases Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.2
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.2
Erythema multiforme rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Skin rash rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Stevens-Johnson syndrome rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
Toxic epidermal necrolysis rare
Disc. AE
0.2 mg/kg 1 times / day multiple, oral (max)
Recommended
Dose: 0.2 mg/kg, 1 times / day
Route: oral
Route: multiple
Dose: 0.2 mg/kg, 1 times / day
Sources: Page: p.3
unhealthy
Health Status: unhealthy
Condition: Chronic lymphatic leukemia|Malignant lymphomas
Sources: Page: p.3
PubMed

PubMed

TitleDatePubMed
Chlorambucil-induced seizure in a patient with nephrotic syndrome.
1999
Chlorambucil induction of HsRad51 in B-cell chronic lymphocytic leukemia.
1999 Aug
Chlorambucil-induced inappropriate antidiuresis in a man with chronic lymphocytic leukemia.
1999 Jan
Mechanisms of mutation induction in germ cells of the mouse as assessed by the specific locus test.
1999 Jul 16
Chlorambucil-induced postclosure exencephaly and axial skeletal abnormalities in rat fetuses.
1999 May-Jun
Chlorambucil-induced acute hepatic failure in a patient with membranous nephropathy.
2000 Aug
The influence of coordinate overexpression of glutathione phase II detoxification gene products on drug resistance.
2000 Aug
Fludarabine compared with chlorambucil as primary therapy for chronic lymphocytic leukemia.
2000 Dec 14
Blastic transformation of splenic lymphoma with villous lymphocytes after a well-controlled chronic phase of more than 10 years.
2000 Feb
Treatment of membranous nephropathy.
2001
Achieving optimal outcomes in chronic lymphocytic leukaemia.
2001
Esters of chlorambucil with 2-substituted 1,4-dihydroxy-9,10-anthraquinones as multifunctional anticancer agents.
2001 Apr
Treatment of Behçet's disease--an update.
2001 Apr
DNA minor groove alkylating agents.
2001 Apr
Fludarabine for chronic lymphocytic leukemia.
2001 Apr 12
Fludarabine for chronic lymphocytic leukemia.
2001 Apr 12
Fludarabine for chronic lymphocytic leukemia.
2001 Apr 12
Reactions of N,N-bis(2-chloroethyl)-p-aminophenylbutyric acid (chlorambucil) with 2'-deoxyguanosine.
2001 Aug
Stage I and II MALT lymphoma: results of treatment with radiotherapy.
2001 Aug 1
Waldenström's macroglobulinemia: clinical course and prognostic factors in 60 patients. Experience from a single hematology unit.
2001 Dec
Waldenström macroglobulinaemia: presenting features and outcome in a series with 217 cases.
2001 Dec
Bcl-2 antisense oligonucleotides enhance the cytotoxicity of chlorambucil in B-cell chronic lymphocytic leukaemia cells.
2001 Jul
The effect of optimal treatment on elderly patients with aggressive non-Hodgkin's lymphoma: more patients treated with unaffected response rates.
2001 Jul
Chlorambucil/prednisone-induced seizures in a patient with non-Hodgkin's lymphoma.
2001 Jun
Treatment of elderly patients with intermediate- and high-grade non-Hodgkin's lymphoma: a retrospective population-based study.
2001 Mar
Chlorambucil drug resistance in chronic lymphocytic leukemia: the emerging role of DNA repair.
2001 Mar
Use of methotrexate in the management of sight-threatening uveitis.
2001 Mar
Role of multidrug resistance protein 1 (MRP1) and glutathione S-transferase A1-1 in alkylating agent resistance. Kinetics of glutathione conjugate formation and efflux govern differential cellular sensitivity to chlorambucil versus melphalan toxicity.
2001 Mar 16
[Paraneoplastic pemphigus: a pustular form during chronic lymphoid leukemia].
2001 May
Induction of mutant lymphocytes in cyclophosphamide- and chlorambucil-treated patients.
2001 May
Novel treatment strategies in chronic lymphocytic leukemia.
2001 May
Giant cell arteritis and renal amyloidosis: report of a case.
2001 Nov
A novel kind of antitumour drugs using sulfonamide as parent compound.
2001 Nov-Dec
Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
2001 Sep
[Vascular purpura in a patient with severe sarcoptic acariasis].
2001 Sep
Novel bicistronic retroviral vector expressing gamma-glutamylcysteine synthetase and the multidrug resistance protein 1 (MRP1) protects cells from MRP1-effluxed drugs and alkylating agents.
2001 Sep 20
Conservative versus immunosuppressive treatment of patients with idiopathic membranous nephropathy.
2002 Jan
Sciatica or spinal lymphoma.
2002 Jan
Patents

Sample Use Guides

0.1 to 0.2 mg/kg body weight daily for 3 to 6 weeks
Route of Administration: Oral
In Vitro Use Guide
Curator's Comment: Chronic lymphocytic leukaemia cells were treated
The inhibition of 3H-thymidine incorporation into the DNA of mitogen-stimulated lymphocytes from patients with chronic lymphocytic leukaemia by chlorambucil was measured in vitro. For the lymphocytes from the untreated patients the mean ID50 was 3.1 ug/ml.
Substance Class Chemical
Created
by admin
on Fri Dec 15 14:58:24 GMT 2023
Edited
by admin
on Fri Dec 15 14:58:24 GMT 2023
Record UNII
18D0SL7309
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
CHLORAMBUCIL
EP   HSDB   INN   MART.   MI   ORANGE BOOK   USP   USP-RS   VANDF   WHO-DD   WHO-IP  
INN  
Official Name English
CB-1348
Code English
CHLORAMBUCIL [JAN]
Common Name English
CHLORAMBUCIL [EP MONOGRAPH]
Common Name English
CHLORAMBUCIL [IARC]
Common Name English
4-(P-(BIS(2-CHLOROETHYL)AMINO)PHENYL)BUTYRIC ACID
Common Name English
CHLORAMBUCILUM [WHO-IP LATIN]
Common Name English
Chlorambucil [WHO-DD]
Common Name English
AMBOCHLORIN
Common Name English
LEUKERAN
Brand Name English
NSC-3088
Code English
CHLORAMBUCIL [VANDF]
Common Name English
ECLORIL
Common Name English
BENZENEBUTANOIC ACID, 4-(BIS(2-CHLOROETHYL)AMINO)-
Common Name English
LYMPHOLYSIN
Common Name English
CHLORAMBUCIL [MART.]
Common Name English
CHLORAMBUCIL [HSDB]
Common Name English
CHLORAMBUCIL [WHO-IP]
Common Name English
NCI-3088
Code English
CHLORAMBUCIL [USP-RS]
Common Name English
chlorambucil [INN]
Common Name English
CHLORAMBUCIL [ORANGE BOOK]
Common Name English
CHLORAMBUCIL [MI]
Common Name English
CHLORAMBUCIL [USP MONOGRAPH]
Common Name English
Classification Tree Code System Code
LIVERTOX NBK548207
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
NDF-RT N0000175558
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
NDF-RT N0000000236
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
NCI_THESAURUS C697
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
WHO-VATC QL01AA02
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
WHO-ATC L01AA02
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
WHO-ESSENTIAL MEDICINES LIST 8.2
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
Code System Code Type Description
WIKIPEDIA
CHLORAMBUCIL
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
EVMPD
SUB06172MIG
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
CAS
305-03-3
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
MERCK INDEX
m3343
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY Merck Index
EPA CompTox
DTXSID7020263
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
ECHA (EC/EINECS)
206-162-0
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
RS_ITEM_NUM
1106001
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
IUPHAR
7143
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
ChEMBL
CHEMBL515
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
HSDB
3026
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
FDA UNII
18D0SL7309
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
CHEBI
28830
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
DRUG BANK
DB00291
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
RXCUI
2346
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY RxNorm
PUBCHEM
2708
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
INN
603
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
NSC
3088
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
DAILYMED
18D0SL7309
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
NCI_THESAURUS
C362
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
MESH
D002699
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
SMS_ID
100000081577
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
DRUG CENTRAL
588
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY
WHO INTERNATIONAL PHARMACOPEIA
CHLORAMBUCIL
Created by admin on Fri Dec 15 14:58:24 GMT 2023 , Edited by admin on Fri Dec 15 14:58:24 GMT 2023
PRIMARY Description: A white or almost white, crystalline or slightly granular powder. Solubility: Practically insoluble in water; freely soluble in ethanol (~750 g/l) TS and acetone R. Category: Cytotoxic drug. Storage: Chlorambucil should be kept in a well-closed container, protected from light. Additional information: CAUTION: Chlorambucil must be handled with care, avoiding contact with the skin and inhalation of airborne particles. Definition: Chlorambucil contains not less than 98.0% and not more than 101.0% of C14H19Cl2NO2, calculated with reference to the anhydrous substance.
Related Record Type Details
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
EP
TRANSPORTER -> SUBSTRATE
BASIS OF STRENGTH->SUBSTANCE
ASSAY (TITRATION)
USP
BINDER->LIGAND
BINDING
Related Record Type Details
METABOLITE ACTIVE -> PARENT
Has antineoplastic activity
Related Record Type Details
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
IMPURITY -> PARENT
CHROMATOGRAPHIC PURITY (HPLC/UV)
EP
Related Record Type Details
ACTIVE MOIETY
A white or almost white, crystalline or slightly granular powder.
Name Property Type Amount Referenced Substance Defining Parameters References
Biological Half-life PHARMACOKINETIC
Volume of Distribution PHARMACOKINETIC